CAJ | 학술논문

目的：观察重组人血管内皮抑制素（恩度）联合腔内化疗治疗恶性胸腔积液的疗效和安全性。方法46例恶性胸腔积液患者非随机分为腔内恩度联合化疗组（治疗组）和腔内化疗组（对照组）。治疗前均先排尽胸水，治疗组在胸腔内注入顺铂（DDP）60 mg和恩度45 mg。对照组除不加入恩度外，其余同治疗组，每周2次，共2～4次，观察两组疗效和安全性。结果治疗组有效率为58．3％，对照组有效率为31．8％，两组差异有统计学意义（χ2＝4．547，P＜0．05）；治疗组生活质量改善率为75．0％，对照组为59．1％，两组差异有统计学意义（χ2＝5．371，P＜0．05）；治疗组毒性反应与对照组相近，未明显增加。结论腔内恩度联合化疗治疗恶性胸腔积液安全有效。
목적：관찰중조인혈관내피억제소（은도）연합강내화료치료악성흉강적액적료효화안전성。방법46례악성흉강적액환자비수궤분위강내은도연합화료조（치료조）화강내화료조（대조조）。치료전균선배진흉수，치료조재흉강내주입순박（DDP）60 mg화은도45 mg。대조조제불가입은도외，기여동치료조，매주2차，공2～4차，관찰량조료효화안전성。결과치료조유효솔위58．3％，대조조유효솔위31．8％，량조차이유통계학의의（χ2＝4．547，P＜0．05）；치료조생활질량개선솔위75．0％，대조조위59．1％，량조차이유통계학의의（χ2＝5．371，P＜0．05）；치료조독성반응여대조조상근，미명현증가。결론강내은도연합화료치료악성흉강적액안전유효。
Objective To study the efficacy and safety of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion.Methods 46 cases with malignant pleural effusion were divided into groups of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion (treatment group)and groups of intracavitary chemotherpy(control group)randomly,pleural effusion of the patients from the two groups were injected cisplatin(DDP)60mg into the thorax and 45mg of endostar,The same therapy applied to the control group except adding endostar,twice a week,in 2 -4 rounds,the efficacy and safety of the two groups were studied.Results The effective rate of the treatment groups was 58.3%,which was higher than 31.8%of the control group (χ2 =4.547,P<0.05).The improvement rate of quality of life was 75.0% in the treatment group,which was higher than 59.1% in the control group (χ2 =5.371,P<0.05).The toxicities of the treatment group were not increased significantly.Conclusion The therapy of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion is effective and secure.